ginosa: results of the
2005-2006 Surveillance Program. M.K. Aranza, D.C. Draghi, M.E.
Jones, C. Thornsberry, D.F. Sahm (Herndon, U.S.; Breda, NL)
P2025 Activity of ceftobiprole against US clinical S. pneumoniae
isolates that are ceftriaxone non-susceptible. T. Davies, K. Bush,
P. Appelbaum (Raritan, Hershey, U.S.)
P2026 Activity of ceftobiprole against Pseudomonas aeruginosa
clinical isolates from Europe collected in 2005-2006. T. Davies, D.
Sahm, R. Flamm, K. Bush (Raritan, Herndon, U.S.)
P2027 Ceftobiprole activity and resistance patterns in
staphylococcal isolates from a recent complicated skin and skin
structure infection study. K. Amsler, M. Jacobs, S. Bajaksouzian,
A. Windau, M. Heep, K. Bush (Raritan, Cleveland, U.S.; Basle,
CH)
O120 Epidemiology of (CA-) MRSA (Room 13b) Characteristics of
complicated skin and skin structure infections due to staphylococci
and the presence of Panton-Valentine leukocidin. R. Strauss, K.
Amsler, M. Jacobs, K. Bush, G. Noel (Raritan, U.S.)
List of Isavuconazole Presentations
P987 Steady-state bioavailability of oral isavuconazole in
healthy volunteers. A. Schmitt-Hoffmann, B. Roos, M. Heep (Basle,
CH)
P1675 QTc measurements during a placebo- and actively controlled
multiple dose study of two different dosing regimens of
isavuconazole. M. Heep, B. Roos, M. Sochor, A. Schmitt-Hoffmann, S.
Van Merle, D. Kappers, P. Voiriot (Basle, CH; Zuidlaren, NL; Nancy,
FR)
P1676 Evaluation of isavuconazole (BAL8557/BAL4815) Etest
compared to broth microdilution antifungal susceptibility testing
against quality control strains and fluconazole susceptible
clinical Candida isolates. M. Heep, P. Grover, N.P. Brown, D. Sahm,
M.E. Jones (Basle, CH; Herndon, U.S.)
P1951 Dose response in neutropenic mice with disseminated
infection of multiple strains of Aspergillus fumigatus with widely
varying MIC and MFC values treated with isavuconazole.P.A. Warn, A.
Parmar, A. Sharp, D.W. Denning (Manc
'"/>
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs
Published Study on Culture Blood-Forming Stem Cells from Human Fat
Tissue as Supporting Near Term Benefits of Banking Adipose (Fat)
Derived Stem Cells2.
Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for
the Treatment of Obesity at the American Diabetes Association 67th
Scientific Session3.
VIVUS Announces Abstract Published at American Diabetes Association
Scientific Sessions4.
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois5.
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions6.
Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 237.
Genaera to Present Preclinical Data on Trodusquemine for the
Treatment of Obesity at the American Diabetes Association 67th
Scientific Sessions8.
VeroScience Late-Breaking Abstract on Cycloset (A Quick Release
Formulation of Bromocriptine Mesylate) Accepted for Poster
Presentation at American Diabetes Association 67th Scientific
Sessions9.
Inspire Announces Presentations at Two European Scientific
Conferences10.
HepaLife Announces Scientific Presentation of PBS-1 Cell Line at
International Influenza Meeting11.
Bentley Late Breaking Abstract Accepted for Poster Presentation at
American Diabetes Association Scientific Sessions